The latest reports show that AS-IV could alleviate heart failure by promoting angiogenesis through the Janus kinase/signal transducers and activators of transcription (JAK/STAT) 3 pathway (Sui et al., 2019), as well as alleviating doxorubicin-induced cardiomyopathy by inhibiting nicotinamide adenine dinucleotide phosphate (NADPH) oxidase-derived oxidative stress (Lin et al., 2019), and protecting cardiac function after myocardial infarction by regulating the phosphatase and tensin homolog/phosphoinositide 3-kinase/protein kinase B (PTEN/PI3K/Akt) signaling pathway (Cheng et al., 2019). Here, AKT1 is linked to cardiomyopathy.